welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
study id #: NCT03167255
condition: Duchenne Muscular Dystrophy
status: active, not recruitingpurpose:
This is an open-label, extension study of NS-065/NCNP-01 administered intravenously once weekly for an additional 144 weeks to boys with DMD who complete Study NS-065/NCNP-01-201.
mechanism of action: Exon-skipping to promote dystrophin production
last updated: March 31, 2019
start date: July 6, 2017
estimated completion: December 2020
phase of development: Phase 2
size / enrollment: 16
This is a Phase II, multicenter, open-label, extension study of NS-065/NCNP-01 administered intravenously once weekly for an additional 144 weeks to boys with DMD who complete Study NS-065/NCNP-01-201. This study will evaluate the safety, tolerability, and clinical efficacy of NS-065/NCNP-01 at dose levels of up to 80 mg/kg/week administered by weekly IV infusion over an additional treatment period of 144 weeks.
Patients who complete the Phase II Dose-finding Study NS-065/NCNP-01-201 are eligible to enroll.
- Number of participants with treatment related Adverse Events as assessed by CTCAE v4.0. [Time Frame: 144 weeks of treatment]
- Change in Time to Stand (TTSTAND) versus matched historical controls. [Time Frame: 144 weeks of treatment]
- Change in Time to Run/Walk 10 meters (TTRW) versus matched historical controls. [Time Frame: 144 weeks of treatment]
- Change in Time to Climb 4 stairs (TTCLIMB) versus matched historical controls. [Time Frame: 144 weeks of treatment]
- North Star Ambulatory Assessment (NSAA) results versus matched historical controls. [Time Frame: 144 weeks of treatment]
- Change in distance traveled in the Six-Minute Walk Test (6MWT) versus matched historical controls. [Time Frame: 144 weeks of treatment]
- Muscle strength as measured by Quantitative Muscle Testing (QMT) versus matched historical controls. [Time Frame: 144 weeks of treatment]
• Completed Study NS-065/NCNP-01-201 through Week 25.
• Willing and able to comply with scheduled visits, investigational product administration plan, and study procedures.
• Stable dose of glucocorticoid (GC), and is expected to remain on the stable dose for the duration of the study.
• Serious or severe adverse event in Study NS-065/NCNP-01-201 that precludes safe use of NS-065/NCNP-01.
• Patient had a treatment which was made for the purpose of dystrophin or its related protein induction after completion of Study NS-065/NCNP-01-201.
• Patient took any other investigational drugs after completion of Study NS-065/NCNP-01-201.
• Patient was judged by the investigator and/or the Sponsor that it was not appropriate to participate in the extension study for other reasons.
A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD)The purpose of this study is to determin...
HT-100 Long-term Study in DMD Patients Who Completed HALO-DMD-02This study, HALO-DMD-03, is a follow-on ...
A Study to Assess the Efficacy and Safety of MNK-1411 in Duchenne Muscular DystrophyThis is a multicenter, double blind, pla...
A Phase IIa Study of TAS-205 for Duchenne Muscular DystrophyThe objective of this study is to evalua...
Solid Biosciences Reports Third Quarter 2018 Financial Results And Provides Business UpdateSolid Biosciences Inc. today reported fi...
Effect of Modulating the nNOS System on Cardiac, Muscular and Cognitive Function in Becker Muscular Dystrophy Patien...This study is done to evaluate whether t...
Study of Eteplirsen in Young Patients With DMD Amenable to Exon 51 SkippingThis is a multicenter, open-label, dose-...
Potential DMD Therapy Vamorolone Shows Positive Effects in Phase 2a Trial, Study ReportsVamorolone, a Duchenne muscular dystroph...
PhaseOut DMD: a Phase 2, proof of concept, clinical study of utrophin modulation with ezutromidThis study investigates the hypothesis t...
MoveDMD: phase 2 trial of edasalonexent, an NF-κB inhibitor, in 4 to 7-year old patients with Duchenne muscular dys...NF-κB is activated from infancy in DMD,...
Roche Letter to the Duchenne CommunityBy now, many have heard about Pfizer's d...